Philip Vitale Net Worth

The estimated Net Worth of Philip J Vitale is at least $49.9 Thousand dollars as of 22 October 2020. Philip Vitale owns over 20,000 units of Perspective Therapeutics Inc stock worth over $49,920 and over the last 11 years he sold ISR stock worth over $0. In addition, he makes $0 as Independent Director at Perspective Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Philip Vitale ISR stock SEC Form 4 insiders trading

Philip has made over 7 trades of the Perspective Therapeutics Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 20,000 units of ISR stock worth $10,400 on 22 October 2020.

The largest trade he's ever made was buying 30,000 units of Perspective Therapeutics Inc stock on 13 November 2018 worth over $12,900. On average, Philip trades about 8,125 units every 129 days since 2014. As of 22 October 2020 he still owns at least 130,000 units of Perspective Therapeutics Inc stock.

You can see the complete history of Philip Vitale stock trades at the bottom of the page.

Philip Vitale biography

Dr. Philip J. Vitale M.D. is a Independent Director of IsoRay, Inc., since 2014. He practiced Urology from 1978 to 2005 at Lovelace Health Systems in Albuquerque. He also served on the Board of Governors for 9 years and held various administrative positions including Chief Medical Officer and Senior Vice President at Lovelace. He was a staff urologist at Albuquerque VA Medical Center from 2005 until his retirement in November 2014. He served as Chief of the Urology section from 2008 to November 2013. Dr. Vitale was also an Assistant Professor at the University of New Mexico, Division of Urology. He is a member of the American Urological Association and the South Central Section of the American Urological Association. Prior to his retirement, Dr. Vitale's clinical trials included: chemotherapy after prostatectomy (cap); a phase III randomized study for high risk prostate carcinoma; RTOG 0415 a phase III randomized study of hypofractionated 3d-crt/IMRT versus conventionally fractionated 3d-crt/IMRT in patients with favorable-risk prostate cancer; RTOG 0815 a phase III prospective randomized trial of dose-escalated radiotherapy with or without short-term androgen deprivation therapy for patients with intermediate-risk prostate cancer; and YP19A1 gene and pharmacogenetics of response to testosterone therapy. Dr. Vitale holds a B.A. in Biology from LaSalle College and obtained his M.D. from the New Jersey College of Medicine and Dentistry. He received his M.S. in Health Services Administration from the College of St. Francis. Dr. Vitale brings to the Board medical expertise in the industries the Company is targeting.

How old is Philip Vitale?

Philip Vitale is 73, he's been the Independent Director of Perspective Therapeutics Inc since 2014. There are no older and 16 younger executives at Perspective Therapeutics Inc.

What's Philip Vitale's mailing address?

Philip's mailing address filed with the SEC is 8849 E. CALLE DE LAS BRISAS, , SCOTTSDALE, AZ, 85255.

Insiders trading at Perspective Therapeutics Inc

Over the last 18 years, insiders at Perspective Therapeutics Inc have traded over $0 worth of Perspective Therapeutics Inc stock and bought 1,651,741 units worth $855,397 . The most active insiders traders include Lori A Woods, Thomas C Lavoy, and Dwight William Babcock. On average, Perspective Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $14,501. The most recent stock trade was executed by Lori A Woods on 13 April 2023, trading 187,500 units of ISR stock currently worth $114,375.

What does Perspective Therapeutics Inc do?

Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.

Complete history of Philip Vitale stock trades at Perspective Therapeutics Inc

Perspective Therapeutics Inc executives and stock owners

Perspective Therapeutics Inc executives and other stock owners filed with the SEC include:

• Lori Woods,
  Chief Executive Officer, Director
• Lori A. Holmes-Woods,
  CEO & Director
• Michael Krachon,
  Executive Vice President of Sales and Marketing
• William Cavanagh,
  Chief Research and Development Officer
• Michael L. Krachon,
  Exec. VP of Sales & Marketing
• Jennifer Streeter,
  COO & VP of HR
• William A. Cavanagh III,
  Chief R&D Officer
• Krista Cline,
  Senior Director of Operations, Corporate Secretary
• Philip Vitale,
  Independent Director
• Alan Hoffmann,
  Independent Director
• Jonathan Hunt,
  Chief Financial Officer, Co-Principal Financial Officer
• Mark Austin,
  Controller, Co-Principal Financial and Principal Accounting Officer
• Jennifer Streeter,
  Chief Operating Officer, Vice President of Human Resources
• Michael McCormick,
  Independent Chairman of the Board
• Krista Cline,
  Sr. Director of Operations & Corp. Sec.
• Mark J. Austin CPA,
  VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec.
• Jonathan R. Hunt,
  CFO & Co-Principal Financial Officer
• Frank Morich,
  Director
• Brien Ragle,
  Controller
• Dwight William Babcock,
  CEO
• Matthew Branson,
  Principal Fin & Acct Officer
• Robert F Iii Williamson,
  Director
• Thomas C Lavoy,
  Director
• Albert Louis Smith,
  Director
• Roger Girard,
  CEO/President
• Robert R Kauffman,
  Director
• Fredric Swindler,
  Vice President
• David Swanberg,
  EVP Operations & Secretary
• Stephen Boatwright,
  Director